Comparison of Persistence Between Adults With Psoriasis Initiating Apremilast or Biologics

Value in Health - United Kingdom
doi 10.1016/j.jval.2016.03.513
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Treatment Persistence in Psoriasis Patients Initiated on Apremilast, Oral Systemics, or Biologic Therapies

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Pss23 - Switch Patterns and Total Costs in Biologic-Naive Patients Initiating Apremilast or a Biologic for the Treatment of Psoriasis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Dermoscopic Features of Nail Psoriasis Treated With Biologics

Journal of Dermatology
DermatologyMedicine
2017English

Predicting Treatment Success With Biologics in Psoriasis

British Journal of Dermatology
DermatologyMedicine
2019English

Psoriasis-Arthritis – Apremilast: Kein Zusatznutzen Ableitbar

Aktuelle Rheumatologie
Rheumatology
2015English

Utility of Apremilast in the Treatment of Psoriasis

International Journal of Basic & Clinical Pharmacology
2018English

Biologics in the Management of Psoriasis

Clinical, Cosmetic and Investigational Dermatology
Dermatology
2009English

The Devil Is in the Data: Differences in Drug Persistence Between SNIIRAM, the French National Health Insurance Database, and Psoriasis Biologics Intervention Registers

British Journal of Dermatology
DermatologyMedicine
2019English

211 Adults With Psoriasis Receive More Opioid Prescriptions Than Adults Without Psoriasis

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy